La cadena de opciones muestra datos clave de las opciones de acciones de Lucid Diagnostics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Lucid Diagnostics..

Lucid Diagnostics (NASDAQ:LUCD) Bolsa, Cadena de Opciones

Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Lucid Diagnostics Inc

News

IMOS

ChipMOS Says It Expects 6.3% FY24 Revenue Growth, With A 5.4% YoY December 2024 Revenue Decline And A 5.7% YoY Q4 Revenue Decline

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio's groundbreaking Titan-1 platform and PacBio's HiFi sequencing technology. By combining Intus Bio's patented strain-level resolution assay and AI-powered analysis with PacBio's renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.

PACB

PacBio and Intus Bio Launch GutID: First AI-Powered, HiFi Sequencing Gut Microbiome Test

<a href="https://www.ilsole24ore.com/art/capri-pronta-cedere-versace-prada-campo-l-acquisto-AGB4dMDC" title="https://www.ilsole24ore.com/art/capri-pronta-cedere-versace-prada-campo-l-acquisto-AGB4dMDC">https://www.ilsole24ore.com/art/capri-pronta-cedere-versace-prada-campo-l-acquisto-AGB4dMDC</a>

Asset Sales

CPRI

Italy's Il Sole 24 Reported Earlier Prada Is A Potential Buyer For Capri's Versace

<ul>
<li>Total revenue is estimated to be&nbsp;$20.4 million&nbsp;and&nbsp;$71.3 million&nbsp;for the fourth quarter and fiscal 2024, respectively, an increase of 39% and 45% over the respective prior year comparable periods;
<ul>
<li>Lung Diagnostics revenue is estimated to be&nbsp;$17.2 million&nbsp;and&nbsp;$64.7 million&nbsp;for the fourth quarter and fiscal 2024, respectively, an increase of 34% and 43% over the respective prior year comparable periods;</li>
<li>Biopharma Services and other revenue is estimated to be&nbsp;$3.2 million&nbsp;and&nbsp;$6.6 million&nbsp;for the fourth quarter and fiscal 2024, respectively, an increase of 68% and 69% over the respective prior year comparable periods; entering 2025 with $12.2 million under contract but not yet recognized as revenue, a 54% increase over the prior year comparable period;</li>
</ul>
</li>
<li>Lung Diagnostic test volumes of 14,600 and 54,300 for the fourth quarter and fiscal 2024, respectively, an increase of 34% and 40% over the respective prior periods;</li>
<li>Cash and cash equivalents of $26.2 million as of December 31, 2024.</li>
</ul>

BDSX

Biodesix Sees Q4 Revenues Of $20.4M And FY24 Revenues Of $71.3M Vs. $70.73M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fli-cycle.com%2F&amp;esheet=54176323&amp;newsitemid=20250110611886&amp;lan=en-US&amp;anchor=Li-Cycle+Holdings+Corp.&amp;index=1&amp;md5=b9bef9707a5d5d97b02aedde3beeca6c">Li-Cycle Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) ("Li-Cycle" or the "Company"), a leading global lithium-ion battery resource recovery company, is pleased to report preliminary commercial and operational highlights for full-year 2024.
Commercial Highlights
Li-Cycle continued to gain commercial traction in 2024, bolstering its position as a preferred lithium-ion battery recycling partner. Its largest customers comprise leading global battery supply chain companies, including EV OEMs, battery manufacturers, miners, and raw material buyers.
In 2024, the largest source of the Company's battery feedstock was a U.S.-headquartered, vertically integrated EV and battery manufacturer with a substantial global EV market share. Throughout 2024, Li-Cycle supported approximately 13 prominent EV manufacturers and approximately 15 key battery cell and material producers with the Company's sustainable recycling services.
"We are pleased to be able to widen our commercial footprint for battery feedstock for our Spoke network in the United States and Germany. Our top source of battery feedstock during the past year was a leading U.S. EV and battery manufacturer and is indicative of our position as a preferred recycling partner for the largest blue-chip companies in the global battery supply chain," said Ajay Kochhar, Li-Cycle President and CEO. "Our sustainable, battery-agnostic recycling technology — which can process full-pack batteries regardless of form factor and without the need to dismantle or discharge — continues to provide value for our global customers."
Rochester Hub and Spoke Operations Highlights
Li-Cycle is continuing to prioritize securing a full financing package to support the construction restart of the Rochester Hub project and to satisfy requirements for first advance under the $475 million loan facility from the U.S. Department of Energy (DOE).
Li-Cycle produced approximately 5,370 tonnes of black mass and equivalents1 ("BM&amp;E") in full-year 2024, and approximately 1,200 tonnes of BM&amp;E in Q4 2024.
The Company is continuing to focus on its Spoke optimization initiatives to establish a financially accretive and self-sufficient Spoke business.
"Our two main goals for the Company are clear: we are focused on securing a full financing package to underpin the restart of construction of the Rochester Hub and starting to draw on the DOE loan, alongside implementing initiatives to enhance Spoke performance and improve cash flow to establish a self-sufficient Spoke business."

LICY

Li-Cycle Strengthens Commercial Footprint, Partners with Major US EV Manufacturer for Battery Recycling in 2024

<ul>
<li>$75 Million in Incremental Term Loan and $30 Million in New Second Lien Notes to Support Operational Improvements, Strategic Priorities and Covenant Relief</li>
<li>Will Pursue Strategic Review of Assets with Key Company Advisors to Maximize Value</li>
<li>Chief Transformation Officer and Board Additions Bolster Company Leadership</li>
<li>Company Withdraws Previously Stated Revenue and Adjusted EBITDA Growth Guidance</li>
</ul>

Guidance

Health Care

General

MODV

Modivcare Has Secured $75M In Incremental Financing, Backed By Stakeholders Across The Capital Structure, And Appointed Chad Shandler As Its Chief Transformation Officer. Existing Investor, Coliseum Capital Management, Has Also Committed $30M To Purchase New Second Lien Senior Notes Due 2029

Mersana Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced positive initial clinical data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin (Emi-Le; XMT-1660), Mersana's lead Dolasynthen ADC candidate targeting B7-H4.

MRSN

Mersana Therapeutics Announces Phase 1 Data for Lead ADC Candidate Targeting B7-H4 in Cancer Treatment

BMO Capital analyst Keith Bachman upgrades Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) from Market Perform to Outperform and raises the price target from $255 to $292.

Upgrades

Price Target

Analyst Ratings

TEAM

BMO Capital Upgrades Atlassian to Outperform, Raises Price Target to $292

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has hiked the price of all variants of its cheapest offering, the Model 3 in China by 3,600 yuan (about $491).
What Happened: The base variant of the Model 3 now starts at 235,500 yuan in China, up from 231,900 yuan. 
While the long-range all-wheel drive variant now starts at 275,500 yuan, the performance variant starts at 339,500 yuan. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Model 3 Variant</td>
<td>New Starting Price</td>
<td>Old Starting Price</td>
</tr>
<tr>
<td>Rear-Wheel Drive</td>
<td>235,500</td>
<td>231,900</td>
</tr>
<tr>
<td>Long Range All-Wheel Drive</td>
<td>275,500</td>
<td>271,900</td>
</tr>
<tr>
<td>Performance</td>
<td>339,500</td>
<td>&nbsp;335,900</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Tesla (All amounts in yuan)</figcaption></figure>
The estimated wait time for all three variants continues to be 1-3 weeks. 
Why It Matters: Tesla also launched a refreshed Model Y in China on Thursday. The refreshed vehicle starts at <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">263,500 yuan on Tesla's website</a>, nearly 5.4% pricier than the older version of the vehicle which started at 249,900 yuan.&nbsp;
China is an important market for Tesla. In 2024, the company reportedly&nbsp;<a href="https://www.benzinga.com/25/01/42782683/tesla-hits-record-ev-sales-in-china-despite-global-dip" target="_blank" rel="noreferrer noopener">sold around 657,000 vehicles in China</a>, marking a growth of 8.8% year-on-year, even while its global annual deliveries fell as compared to 2023.
Tesla reported global <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a> vehicles in 2024, down from full-year deliveries of 1.81 million in 2023, marking the first decline in over a decade.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42906684/blue-origin-pushes-new-glenn-launch-to-no-earlier-than-sunday">Jeff Bezos&#8217; Blue Origin Pushes New Glenn Launch To No Earlier Than Sunday Due To Adverse Weather Conditions</a></li>
</ul>
Photo courtesy: Tesla

Tech

TSLA

Tesla Model 3 Prices Rise In China As Refreshed Model Y Debuts

BMO Capital analyst Michael Zaremski upgrades Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) from Market Perform to Outperform and raises the price target from $372 to $453.

BMO Capital Upgrades Everest Group to Outperform, Raises Price Target to $453

Macro Economic Events

Econ #s

Economics

France Consumer Spending (MoM) For November 0.3% Vs. 0.1% Est.; -0.3% (Revised) Prior

BMO Capital analyst Kostas Biliouris upgrades Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) from Market Perform to Outperform and maintains the price target from $34 to $34.

DTIL

BMO Capital Upgrades Precision BioSciences to Outperform, Maintains Price Target to $34

Baird analyst Jon Vruwink downgrades Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) from Outperform to Neutral and raises the price target from $89 to $99.

Downgrades

QTWO

Baird Downgrades Q2 Holdings to Neutral, Raises Price Target to $99

Shares of Zoomcar Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) rose sharply in today's pre-market trading after the company announced a significant achievement in its financial performance, reporting the highest-ever unaudited and unreviewed contribution profit for <a href="https://www.benzinga.com/25/01/42894964/zoomcar-achieves-highest-ever-december-profit-driven-by-17-increase-in-bookings">December 2024</a>.
The company achieved $494,506 in contribution profit for the month, which was sufficient to cover its operational costs in India. It is to be noted that Zoomcar currently only operates in India and does not incur operational costs in any other country.
Zoomcar Holdings shares jumped 40.5% to $2.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Vision Marine Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) gained 102% to $3.07 in pre-market trading after the company partnered with Calip Group to produce advanced cooling plates for electric boat batteries.</li>
<li>Bridger Aerospace Group Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) gained 56.3% to $4.36 in pre-market trading after surging 12% on Wednesday.</li>
<li>Mars Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) rose 44.5% to $3.15 in pre-market trading after the company announced it sees a growth path after its successful de-SPAC transaction.</li>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) rose 35.3% to $2.53 in pre-market trading after the company announced breakthrough in true all-solid-state battery technology.</li>
<li>Senseonics Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SENS#NYSE">SENS</a>) gained 29.6% to $0.56 in pre-market trading after the company announced business updates including preliminary 2024 results, 365 launch update and cancellation of special meeting.</li>
<li>Precision BioSciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) gained 27.3% to $5.73 in pre-market trading after the company's partner iECURE has reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the phase 1/2 OTC-HOPE study.</li>
<li>Intrusion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) gained 25% to $2.50 in pre-market trading after falling 23% on Wednesday.</li>
<li>Penguin Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) gained 15.8% to $22.15 in pre-market trading after the company signed AI data center collaboration agreement with SK Telecom and SK hynix.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 12.2% to $4.96 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>IGM Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) fell 66.3% to $2.09 in pre-market trading as the company halted further development of Imvotamab and IGM-2644 and plans reducing its workforce by 73%.</li>
<li>Calidi Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) fell 31.1% to $0.93 in today's pre-market trading after announcing a proposed public offering.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) fell 30.1% to $42.42 in pre-market trading after declining around 6% on Wednesday.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares fell 29.1% to $5.75 in pre-market trading after surging over 40% on Wednesday.</li>
<li>Aviat Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) fell 25.5% to $14.00 in pre-market trading.</li>
<li>Silo Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) dipped 22.2% to $1.33 in pre-market trading. Silo Pharma shares jumped 57% on Wednesday after the company announced it was awarded a US patent for its PTSD treatment titled &#8216;Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.&#8217;</li>
<li>CURRENC Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares fell 21.6% to $3.07 in pre-market trading after jumping 182% on Wednesday.</li>
<li>European Wax Center Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) shares tumbled 20.4% to $5.10 in pre-market trading.</li>
<li>Vinci Partners Investments Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) shares dipped 15.5% to $8.10 in pre-market trading.</li>
<li>ZIM Integrated Shipping Services Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) declined 7.4% to $19.16  in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnings</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVNW

BAER

CLDI

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

EWCZ

IGMS

INTZ

MVST

Penguin Solutions, Inc. - Ordinary Shares

PENG

SENS

SILO

STAI

VINP

VMAR

XXII

ZCAR

Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) continues to &#8220;reshape modern warfare&#8221; despite recent market volatility, with shares down 10.51% year-to-date after surging over 306% in the past year, according to co-founder Joe Lonsdale.
What Happened: &#8220;It&#8217;s great to see Palantir being recognized as an extremely valuable company,&#8221; Lonsdale said during a CNBC <a href="https://www.youtube.com/watch?v=RBAGWBQNogU">appearance</a> on Thursday, highlighting the company&#8217;s $155 billion market capitalization that now exceeds traditional defense contractor Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>).
The data analytics giant&#8217;s rapid growth gained even more momentum after President-elect Donald Trump&#8216;s victory, with shares soaring more than 50% from the election to year-end.
CEO Alex Karp emphasized the <a href="https://www.benzinga.com/markets/equities/24/12/42356725/alex-karp-supports-doge-as-trump-taps-palantirs-shyam-shankar-for-border-security-role-cannot-have-a-better-person-than-musk">company&#8217;s military applications</a>, stating, &#8220;We&#8217;ve managed our model in AI so that it actually delivers value — on the battlefield, to bring soldiers home, to kill enemies, or commercially, to change margins.&#8221;
This transformation from a data organization platform to an AI powerhouse nearly didn&#8217;t happen. Lonsdale revealed on the Shawn Ryan show that Palantir &#8220;came really close to dying&#8221; in its early years before <a href="https://www.benzinga.com/markets/equities/24/12/42570755/joe-lonsdale-reveals-palantirs-close-to-dying-moment-credits-alex-karp-for-securing-key-contracts-with-fbi-and-cia">Karp secured crucial FBI and CIA contracts</a>. &#8220;A few of our top guys were basically ready to quit,&#8221; he recalled, highlighting the company&#8217;s dramatic turnaround.
See Also: <a href="https://www.benzinga.com/news/25/01/42905013/nvidia-slams-bidens-country-specific-chip-rules-legacy-that-will-be-criticized">Nvidia Slams Biden&#8217;s Country-Specific Chip Rules: &#8216;Legacy That Will Be Criticized&#8217;</a>
Wedbush Securities analyst Dan Ives remains bullish, <a href="https://www.benzinga.com/markets/equities/24/12/42696805/palantir-touted-as-next-oracle-by-dan-ives-here-is-why-the-wedbush-analyst-called-the-company-a-table-pounder">predicting 2025 will mark a breakthrough year</a> for Palantir&#8217;s AI platform. The company&#8217;s expanding influence is further evidenced by its recent partnership with Amazon Web Services to provide Anthropic&#8217;s Claude AI models to U.S. intelligence agencies.
Why It Matters: While 44% of Palantir&#8217;s revenue still comes from government contracts, Lonsdale emphasized that the majority of growth now stems from commercial applications. 
This diversification, coupled with the company&#8217;s technological edge over traditional defense contractors, positions Palantir at the forefront of both military modernization and commercial AI deployment despite recent market fluctuations.
&#8220;There&#8217;s a growing recognition worldwide of the need for cutting-edge defense solutions,&#8221; Lonsdale said. &#8220;Interestingly, modest reductions in defense budgets can benefit newer, innovative defense firms. Legacy contractors often operate with inefficiencies that make their solutions far more expensive.&#8221;
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42906684/blue-origin-pushes-new-glenn-launch-to-no-earlier-than-sunday">Jeff Bezos&#8217; Blue Origin Pushes New Glenn Launch To No Earlier Than Sunday Due To Adverse Weather Conditions</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

PLTR

Palantir Co-Founder Joe Lonsdale Touts Lead Over Traditional Contractors Amid Stock Dip: Analyst Says 2025 To Be A Breakthrough Year

Amid the ongoing devastation caused by wildfires in Los Angeles, Warren Buffett&#8216;s Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), the nation&#8217;s largest property and casualty insurer, is expected to experience minimal financial impact, while other insurers face significant exposure due to its substantial presence in California&#8217;s homeowners insurance market.
What Happened: Berkshire Hathaway&nbsp;is not a major player in the California homeowners insurance market, hence the impact of the wildfires is expected to be minimal. However, other insurers like&nbsp;Mercury General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>),&nbsp;Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>),&nbsp;Chubb Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), and&nbsp;Travelers Companies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>)&nbsp;could face substantial losses, Barron&#8217;s <a href="https://www.barrons.com/amp/articles/berkshire-hathaway-los-angeles-fire-losses-8e0e5591">reported </a>on Friday.
J.P. Morgan analyst Jimmy Bhullar&nbsp;noted on Thursday that insured losses from the fires might surpass $20 billion, setting a new record for wildfire losses in California. 
Mercury General, heavily reliant on California for its premiums, could be the most vulnerable relative to its size. The company wrote over $700 million in homeowners insurance&nbsp;premiums in the state during&nbsp;the first nine months of&nbsp;2024. Mercury&#8217;s stock fell 6.5% on Wednesday, reflecting investor concerns about its exposure to the fires.
Meanwhile,&nbsp;Berkshire Hathaway could see losses of about $600 million, a minor fraction of its insurance capital. The company might benefit from potential increases in insurance pricing following the fires.
Why It Matters: The ongoing wildfires in Los Angeles have <a href="https://www.benzinga.com/25/01/42899028/la-wildfire-damages-estimated-above-52-billion-california-property-insurance-crisis">caused extensive damage</a>, with estimates suggesting total damages could exceed $52 billion, according to&nbsp;Accuweather. More than 2,000 structures have been damaged or destroyed, with further destruction anticipated as red flag warnings persist.
The fires have ignited concerns among investors regarding the stability of <a href="https://www.benzinga.com/markets/equities/25/01/42906089/california-wildfires-ignite-concerns-for-insurance-stocks-here-are-some-insurance-etfs-which-could-be-impacted">California-based insurance stocks</a> and ETFs. The Eaton and Palisades fires alone have ravaged over 10,000 structures, leading to 10 confirmed fire-related deaths. As the crisis unfolds, insurers like&nbsp;Allstate&nbsp;and&nbsp;Travelers&nbsp;are under scrutiny, given their significant roles in the California market. The California FAIR Plan, a state-backed insurer of last resort, is also heavily involved in insuring homes in the affected areas.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, on Friday during pre-market hours, Berkshire Hathaway was showing minimal upward movement by 0.022% while Chubb had dropped by 3.60%, Travelers Company was down by 4.85% while Allstate fell by 6.15%. 
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/42906229/dow-surges-over-100-points-following-fed-minutes-investor-sentiment-declines-greed-index-remains-in-fear-zone">Dow Surges Over 100 Points Following Fed Minutes: Investor Sentiment Declines, Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Representative Image via Wikimedia Commons

Warren Buffett's Berkshire Hathaway To Have Minimal Impact From LA Wildfires, But Insurers Like Mercury General, Chubb Face Higher Risk

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) disclosed an agreement with NASA to include its Neutron rocket under the existing Venture-Class Acquisition of <a href="https://www.benzinga.com/pressreleases/25/01/b42902495/rocket-lab-selected-by-nasa-to-provide-neutron-launch-services-under-vadr-launch-contract" target="_blank" rel="noreferrer noopener">Dedicated and Rideshare contract</a>.
The Neutron, Rocket Lab&#8217;s reusable medium-lift launch vehicle, will enable the company to expand its capabilities by supporting a variety of missions, including CubeSats, Class D missions, and other payload types across multiple orbits.
Neutron is engineered to offer both commercial and government clients a dependable launch solution, with the capacity to deliver up to 13,000 kg to low Earth orbit.
The rocket is specifically suited for deploying satellite constellations, supporting national security missions, and carrying science and exploration payloads.
Beyond customer missions, Neutron plays a critical role in Rocket Lab&#8217;s long-term strategy to become a fully integrated space company, capable of building, launching, and managing its own satellite constellations while providing space-based services.
Rocket Lab has already delivered several VADR missions with its Electron rocket, demonstrating rapid launch turnarounds.
Notably, the company executed consecutive launches for NASA&#8217;s PREFIRE mission within a two-week span and completed back-to-back launches in May 2023 for the TROPICS mission.
Yesterday, the company successfully completed the Preliminary Design Review for the $515 million Space Development Agency contract, advancing design of 18 satellites for U.S. <a target="_blank" href="https://www.benzinga.com/25/01/42900671/rocket-lab-completes-pdr-for-515m-sda-satellite-contract" rel="noreferrer noopener">defense communications and missile tracking</a>.
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>).
Price Action: RKLB shares are up 4.71% at $28.65 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/25/01/42859212/rocket-lab-surge-sparks-renewed-interest-in-space-focused-etfs-3-funds-in-focus" target="_blank" rel="noreferrer noopener">Rocket Lab Surge Sparks Renewed Interest In Space-Focused ETFs: 3 Funds In Focus</a></li>
</ul>

Large Cap

Contracts

ARKQ

ARKX

RKLB

Rocket Lab Expands NASA Partnership With Neutron Under VADR Contract

GLXG

Galaxy Payroll Group Says It Has Gained Worldwide Recognition For Its Professional Services And Innovative Solutions

Roth MKM analyst Boobalan Pachaiyappan initiates coverage on Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy rating and announces Price Target of $7.

Initiation

RVPH

Roth MKM Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $7

Truist Securities analyst Asthika Goonewardene initiates coverage on BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy rating and announces Price Target of $172.

BNTX

Truist Securities Initiates Coverage On BioNTech with Buy Rating, Announces Price Target of $172

Lucid Diagnostics Inc. ( ($LUCD) ) has released its Q3 earnings. Here is a breakdown of the information Lucid Diagnostics Inc. presented to its inv...

Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion

BTIG analyst Mark Massaro reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report) yesterday and set a price target of $2.50. Mark Mas...

Lucid Diagnostics: Buy Rating Affirmed on Strong Revenue Growth and Future Expansion Potential

Kyle Mikson CFA, an analyst from Canaccord Genuity, maintained the Buy rating on Lucid Diagnostics (LUCD – Research Report). The associated price t...

Lucid Diagnostics: Strong Growth Potential Justifies Buy Rating

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a pri...

Lucid Diagnostics: Strong Demand and Strategic Advancements Drive 'Buy' Rating

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has submitted its complete clinical evidence package for its EsoGuard Es...

Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test

Lucid Diagnostics ( ($LUCD) ) has issued an announcement. Lucid Diagnostics Inc. recently secured $21.95 million through the sale of Senior Secured...

Lucid Diagnostics' Strategic Financial Maneuvering and Agreements

Lucid Diagnostics (LUCD) and subsidiary of PAVmed (PAVM), announced that the manuscript for its CLinical Utility of EsoGuard, or CLUE, study has be...

Lucid announces publication on EsoGuard in peer-reviewed journal Medicina

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), has entered into a strategic partnership with VITALExam, a comprehensive medical care prov...

Lucid Diagnostics partners for esophageal precancer detection for firefighters

Lucid Diagnostics receives 180-day extension by Nasdaq

Lucid Diagnostics (LUCD) announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market ...

Lucid Diagnostics granted 180-day extension by Nasdaq to regain compliance

LUCD

PAVM

Press Releases

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

Comments

Lucid Diagnostics

Lucid Diagnostics (LUCD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL